Valuation: CorMedix Inc.

Market Cap 623M 548M 509M 468M 878M 60.32B 894M 6.09B 2.37B 29.42B 2.34B 2.29B 102B P/E 2026 *
15.8x
P/E 2027 * 90.2x
Enterprise Value 623M 548M 509M 468M 878M 60.32B 894M 6.09B 2.37B 29.42B 2.34B 2.29B 102B EV / Sales 2026 *
1.86x
EV / Sales 2027 * 2.18x
Free-Float
92.47%
Yield 2026 *
-
Yield 2027 * -
1 day+0.44%
1 week-3.80%
Current month+1.59%
1 month-7.27%
3 months+8.80%
6 months+9.70%
Current year-31.43%
1 week 7.69
Extreme 7.69
8.53
1 month 7.5
Extreme 7.495
8.98
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
14.96
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 09/05/2022
Director of Finance/CFO 54 28/08/2025
Compliance Officer 66 11/12/2023
Director TitleAgeSince
Director/Board Member 67 05/08/2015
Chairman 81 02/08/2017
Director/Board Member 70 15/08/2011
Date Insider Type Main position Quantity % Market Cap.
04/02/26 Free

General Counsel

36,006 0.0457%
04/02/26 Free

Chief Executive Officer

77,156 0.0979%
04/02/26 Free

Chief Operating Officer

36,006 0.0457%
Change 5-day change 1-year change 3-year change Capi.($)
+0.44%-3.80%-31.37%+108.77% 623M
+2.30%+2.27%+55.43%+19.98% 315B
+1.72%+0.94%+24.00%-11.62% 67.93B
+2.37%+2.38%+35.56%+85.65% 9.23B
-1.26%-1.72%+4.64%-3.98% 8.43B
+3.78%+1.92%-21.25%-6.67% 4.07B
+0.07%-9.52%-5.52%+22.21% 3.77B
+1.71%+2.73%-42.88%+11.90% 3.54B
+0.72%-1.80%+43.59%+57.54% 2.72B
-0.30%-6.60%+4.82%-10.21% 2.13B
Average +1.12%+0.70%+6.70%+27.36% 41.73B
Weighted average by Cap. +2.02%+3.19%+46.25%+15.72%

Financials

2026 *2027 *
Net sales 335M 294M 273M 251M 471M 32.4B 480M 3.27B 1.28B 15.8B 1.26B 1.23B 54.83B 285M 251M 233M 214M 402M 27.62B 409M 2.79B 1.09B 13.47B 1.07B 1.05B 46.74B
Net income 47.14M 41.46M 38.52M 35.43M 66.44M 4.57B 67.63M 461M 180M 2.23B 177M 173M 7.73B 8.61M 7.57M 7.03M 6.47M 12.13M 834M 12.35M 84.12M 32.81M 407M 32.32M 31.62M 1.41B
Net Debt - -
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
23/07/26 US$7.975 +0.44% 222,973
22/07/26 US$7.940 -3.05% 860,115
21/07/26 US$8.190 +5.27% 1,038,432
20/07/26 US$7.780 -7.60% 1,156,381
17/07/26 US$8.420 +1.57% 694,737
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.940USD
Average target price
15.00USD
Spread / Average Target
+88.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRMD Stock